Clinical trialNCT05874921RecruitingObservational

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

SponsorUroGen Pharma Ltd.Enrollment400Carcinoma, Transitional CellTransitional Cell Carcinoma of Renal PelvisUrothelial Cancer of Renal PelvisUrothelial CarcinomaUrothelial Carcinoma RecurrentUrothelial Carcinoma Ureter+2 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Adam Feldman, MD
Massachusett&#39;s General Hospital
Principal Investigator
clinicaltrials.gov ↗
Solomon Woldu, MD
UT Southwestern Medical Center at Dallas
Principal Investigator
clinicaltrials.gov ↗
Yair Lotan, MD
UT Southwestern Medical Center at Dallas
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Providence St. Johns Health Center
Santa Monica, California, United States
Recruiting
University of Florida
Gainesville, Florida, United States
Recruiting
Mount Sinai Medical Center of Florida, Inc.
Miami, Florida, United States
Recruiting
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
Tampa, Florida, United States
Recruiting
Northwestern University
Chicago, Illinois, United States
Recruiting
Indiana University
Indianapolis, Indiana, United States
Recruiting
the State University of Iowa
Iowa City, Iowa, United States
Recruiting
Chesapeake Urology
Baltimore, Maryland, United States
Recruiting
Johns Hopkins Medical Center
Baltimore, Maryland, United States
Recruiting
Mass General Hospital (mgh)
Boston, Massachusetts, United States
Recruiting
the Brigham and Womens Hospital
Boston, Massachusetts, United States
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
Recruiting
University of Missouri
Columbia, Missouri, United States
Recruiting
Rutgers
New Brunswick, New Jersey, United States
Recruiting
the Feinstein Institutes for Medical Research
Lake Success, New York, United States
Recruiting
Nyu Grossman School of Medicine
New York, New York, United States
Recruiting
Suny Upstate
Syracuse, New York, United States
Recruiting
the University of North Carolina Chapel Hill
Chapel Hill, North Carolina, United States
Recruiting
Ohio State University
Columbus, Ohio, United States
Recruiting
Medical University of South Carolina
Charleston, South Carolina, United States
Recruiting
Ut Southwestern Medical Center
Dallas, Texas, United States
Recruiting
the University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Jelmyto for pyelocalyceal solution

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 Nov 2023
Primary completion: 30 Apr 2026
Completion: 31 Jan 2028
Last update posted: 28 Feb 2025
Registered enrollment: 400
Registry id: NCT05874921

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.